The agenda features a mix of clinical updates and lively debates on provocative scientific topics in the field, including emerging concepts and therapies in GI, rare tumors, cancers affecting the gastrointestinal tract, and much more.

All Industry supported CME educational sessions will be available at no cost. Learners can access this material via the HMP Education Network. Learn more here.

Agenda

October 19-20 | Dallas

Available DatesRegister

Saturday October 19, 2024

  • 8:00 AM – 8:05 AM

    Welcome

    • Co-Chair
      • Cathy EngMD, FACP, FASCO
      • Yelena JanjigianMD
  • 8:05 AM – 8:20 AM

    Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? - PD-1 INHIBITORS

    • Presenter
      • Ryan MoyMD, PhD
  • 8:20 AM – 8:35 AM

    Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? - CLDN18.2

    • Presenter
      • Michael GibsonMD, PhD
  • 8:35 AM – 8:45 AM

    Debate: Best Targeted Therapy for First-Line Gastroesophageal Cancer: PD-1 Inhibitors or Claudin-18.2 (CLDN18.2)? - DISCUSSION

    • Panelist
      • Michael GibsonMD, PhD
      • Ryan MoyMD, PhD
  • 8:45 AM – 9:00 AM

    Debate: MSI Tumors: Does Anatomic Location Affect the Management? - YES

    • Presenter
      • Lakshmi RajdevMD, MS
  • 9:00 AM – 9:15 AM

    Debate: MSI Tumors: Does Anatomic Location Affect the Management? - NO

    • Presenter
      • Nataliya UbohaMD, PhD
  • 9:15 AM – 9:25 AM

    Debate: MSI Tumors: Does Anatomic Location Affect the Management? Yes vs No - DISCUSSION

    • Panelist
      • Lakshmi RajdevMD, MS
      • Nataliya UbohaMD, PhD
  • 9:25 AM – 9:35 AM

    Break

  • 9:35 AM – 10:35 AM

    Non-CME Innovation Theater - Sponsored by IPSEN

  • 10:35 AM – 11:15 AM

    Optimizing Outcomes in Advanced/Metastatic Gastric and Gastroesophageal Junction Cancer: A Focus on Novel and Emerging HER2-Negative Targeted Treatment Strategies

    • Presenter
      • Thomas CartwrightMD
  • 11:15 AM – 11:30 AM

    Debate: Management of Gastric Cancer With Limited Peritoneal Carcinomatosis - Cytoreduction and HIPEC for All - YES

    • Presenter
      • Maheswari SenthilMD
  • 11:30 AM – 11:45 AM

    Debate: Management of Gastric Cancer With Limited Peritoneal Carcinomatosis - Cytoreduction and HIPEC for All - NO

    • Presenter
      • Nataliya UbohaMD, PhD
  • 11:45 AM – 11:55 AM

    Debate: Management of Gastric Cancer With Limited Peritoneal Carcinomatosis - Cytoreduction and HIPEC for All: Yes vs No - DISCUSSION

    • Panelist
      • Maheswari SenthilMD
      • Nataliya UbohaMD, PhD
  • 11:55 AM – 12:05 PM

    Break

  • 12:05 PM – 1:05 PM

    Non-CME Innovation Theater - Sponsored by Exelixis

  • 1:05 PM – 1:35 PM

    Exhibit Hall

  • 1:35 PM – 2:15 PM

    Targeting HER2 Overexpression in Gastroesophageal and Colorectal Cancers: Novel and Emerging Options

    • Presenter
      • Thomas CartwrightMD
  • 2:15 PM – 2:30 PM

    Debate: Germline Testing for Gastrointestinal Tumors for all Irrespective of Tumor Origin - YES

    • Presenter
      • Heather HampelMS, CGC
  • 2:30 PM – 2:45 PM

    Debate: Germline Testing for Gastrointestinal Tumors for all Irrespective of Tumor Origin - NO

    • Presenter
      • Michael HallMD, MS
  • 2:45 PM – 2:55 PM

    Debate: Germline Testing for Gastrointestinal Tumors for all Irrespective of Tumor Origin: Yes vs No - DISCUSSION

    • Panelist
      • Heather HampelMS, CGC
      • Michael HallMD, MS
  • 2:55 PM – 3:05 PM

    Break

  • 3:05 PM – 4:05 PM

    Non-CME Innovation Theater - Sponsored by TAIHO

  • 4:05 PM – 4:45 PM

    Understanding the Latest Developments in the Rapidly Evolving Targeted Therapy and Immunotherapy Treatment Landscape of Advanced Cholangiocarcinoma

    • Presenter
      • Midhun MallaMD MS
  • 4:45 PM – 5:00 PM

    Debate: Is There A Role for Immune Checkpoint Inhibition Outside of A Clinical Trial in Microsatellite Stable (MSS) Patients? - YES

    • Presenter
      • Kristen CiomborMD, MSCI
  • 5:00 PM – 5:15 PM

    Debate: Is There A Role for Immune Checkpoint Inhibition Outside of A Clinical Trial in Microsatellite Stable (MSS) Patients? - NO

    • Presenter
      • Smitha KrishnamurthiMD
  • 5:15 PM – 5:25 PM

    Debate: Is There A Role for Immune Checkpoint Inhibition Outside of A Clinical Trial in Microsatellite Stable (MSS) Patients? Yes vs No - DISCUSSION

    • Panelist
      • Kristen CiomborMD, MSCI
      • Smitha KrishnamurthiMD
  • 5:25 PM – 6:25 PM

    Welcome Reception - Sponsored by Natera

Sunday October 20, 2024

  • 8:00 AM – 8:05 AM

    Welcome

    • Co-Chair
      • Cathy EngMD, FACP, FASCO
      • Yelena JanjigianMD
  • 8:05 AM – 8:20 AM

    Debate: Transarterial Chemoembolization for Hepatocellular Carcinoma with Immune Checkpoint Blockade: Skip it or Do it? - DO IT

    • Presenter
      • Andrew MarsalaMD
  • 8:20 AM – 8:35 AM

    Debate: Transarterial Chemoembolization for Hepatocellular Carcinoma with Immune Checkpoint Blockade: Skip it or Do it? - SKIP IT

    • Presenter
      • Armeen MahvashMD
  • 8:35 AM – 8:45 AM

    Debate: Transarterial Chemoembolization for Hepatocellular Carcinoma with Immune Checkpoint Blockade: Skip it or Do it? - DISCUSSION

    • Panelist
      • Andrew MarsalaMD
      • Armeen MahvashMD
  • 8:45 AM – 9:00 AM

    Debate: Cholangiocarcinoma - Immune Checkpoint Blockade for All - YES

    • Presenter
      • Rachna ShroffMD, MS, FASCO
  • 9:00 AM – 9:15 AM

    Debate: Cholangiocarcinoma - Immune Checkpoint Blockade for All - NO

    • Presenter
      • Milind JavleMD
  • 9:15 AM – 9:25 AM

    Debate: Cholangiocarcinoma - Immune Checkpoint Blockade for All: Yes vs No - DISCUSSION

    • Panelist
      • Milind JavleMD
      • Rachna ShroffMD, MS, FASCO
  • 9:25 AM – 9:35 AM

    Break

  • 9:35 AM – 10:35 AM

    Non-CME Innovation Theater - Sponsored by Merck

  • 10:35 AM – 11:05 AM

    Exhibit Hall

  • 11:05 AM – 11:45 AM

    Improving Outcomes for Advanced/Unresectable Hepatocellular Carcinoma: Immune Checkpoint Inhibitor-Based Strategies in First-Line Therapy

    • Presenter
      • Ghassan Abou-AlfaMD, MBA
  • 11:45 AM – 12:00 PM

    Debate: Is Hepatic Arterial Infusion Pump (HAI) Therapy Worthwhile in Previously Treated mCRC Patients? - YES

    • Presenter
      • Adam YoppMD
  • 12:00 PM – 12:15 PM

    Debate: Is Hepatic Arterial Infusion Pump (HAI) Therapy Worthwhile in Previously Treated mCRC Patients? - NO

    • Presenter
      • Sekhar PadmanabhanMD
  • 12:15 PM – 12:25 PM

    Debate: Is Hepatic Arterial Infusion Pump (HAI) Therapy Worthwhile in Previously Treated mCRC Patients? Yes vs No - DISCUSSION

    • Panelist
      • Adam YoppMD
      • Sekhar PadmanabhanMD
  • 12:25 PM – 12:35 PM

    Break

  • 12:35 PM – 1:35 PM

    Non-CME Innovation Theater - Sponsored by Takeda

  • 1:35 PM – 2:15 PM

    Optimizing Treatment of Non-MSI-H Metastatic Colorectal Cancer with Newer and Emerging Options

    • Presenter
      • Syed KazmiMD
  • 2:15 PM – 2:30 PM

    Debate: Is ctDNA Ready for Prime Time for Detection of Molecular Residual Disease? - YES

    • Presenter
      • Arvind DasariMD
  • 2:30 PM – 2:45 PM

    Debate: Is ctDNA Ready for Prime Time for Detection of Molecular Residual Disease? - NO

    • Presenter
      • Jason ZellDO, MPH
  • 2:45 PM – 2:55 PM

    Debate: Is ctDNA Ready for Prime Time for Detection of Molecular Residual Disease? Yes vs No - DISCUSSION

    • Panelist
      • Arvind DasariMD
      • Jason ZellDO, MPH
  • 2:55 PM – 3:10 PM

    Break

  • 3:10 PM – 3:25 PM

    Debate: Short-Course vs. Long-Course Neoadjuvant Radiation Therapy in Rectal Cancer - SHORT-COURSE

    • Presenter
      • Prajnan DasMD, MS, MPH, FACR, FASTRO
  • 3:25 PM – 3:40 PM

    Debate: Short-Course vs. Long-Course Neoadjuvant Radiation Therapy in Rectal Cancer - LONG-COURSE

    • Presenter
      • Natalie LockneyMD
  • 3:40 PM – 3:50 PM

    Debate: Short-Course vs. Long-Course Neoadjuvant Radiation Therapy in Rectal Cancer - DISCUSSION

    • Panelist
      • Natalie LockneyMD
      • Prajnan DasMD, MS, MPH, FACR, FASTRO
  • 3:50 PM – 4:05 PM

    Debate: Repeat NGS Testing is Needed in All Patients With Metastatic Colorectal Cancer (mCRC) at Progression of Disease - YES

    • Presenter
      • Hagen KenneckeMD, MHA, FRCPC
  • 4:05 PM – 4:20 PM

    Debate: Repeat NGS Testing is Needed in All Patients With Metastatic Colorectal Cancer (mCRC) at Progression of Disease - NO

    • Presenter
      • Ardaman ShergillMD, MSPH
  • 4:20 PM – 4:30 PM

    Debate: Repeat NGS Testing is Needed in All Patients With Metastatic Colorectal Cancer (mCRC) at Progression of Disease: Yes vs No - DISCUSSION

    • Panelist
      • Ardaman ShergillMD, MSPH
      • Hagen KenneckeMD, MHA, FRCPC